One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer - Summary - MDSpire

One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer

  • By

  • Darren M. C. Poon

  • Jing Yuan

  • Oi Lei Wong

  • Bin Yang

  • Mei Yan Tse

  • Ka Ki Lau

  • Sin Ting Chiu

  • Peter Ka-Fung Chiu

  • Chi Fai Ng

  • Ka Lun Chui

  • Yiu Ming Kwong

  • Wai Kit Ma

  • Kin Yin Cheung

  • George Chiu

  • Siu Ki Yu

  • February 23, 2024

  • 0 min

Share

Objective:

To investigate the clinical use of rectal spacer for adaptive MRgSBRT in localized prostate cancer patients and report patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) up to a median follow-up of 1 year, emphasizing their significance in evaluating treatment efficacy.

Key Findings:
  • MRgSBRT with rectal spacers resulted in improved rectal sparing and reduced toxicity, measured by specific clinical metrics.
  • Patient-reported outcomes indicated favorable quality of life post-treatment.
  • The study demonstrated the feasibility and safety of using rectal spacers in MRgSBRT.
Interpretation:

The use of rectal spacers in MRgSBRT appears to enhance treatment outcomes by minimizing rectal toxicity and improving patient quality of life.

Limitations:
  • The study is observational and lacks a control group for comparison, which may introduce biases in the findings.
  • Long-term data on toxicities and PROs beyond one year are still needed.
Conclusion:

The findings support the clinical application of rectal spacers in MRgSBRT for localized prostate cancer, highlighting benefits in toxicity reduction and patient quality of life.

Original Source(s)

One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer

  • by Darren M. C. Poon, Jing Yuan, Oi Lei Wong, Bin Yang, Mei Yan Tse, Ka Ki Lau, Sin Ting Chiu, Peter Ka-Fung Chiu, Chi Fai Ng, Ka Lun Chui, Yiu Ming Kwong, Wai Kit Ma, Kin Yin Cheung, George Chiu, Siu Ki Yu

  • February 23, 2024

Related Content

Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

Therapy of clinical stage IIA and IIB seminoma: a systematic review

More Than 145 Dana-Farber Affiliated Faculty Named as 2026 Top Doctors™ in Boston Magazine

Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties

  • by

  • January 27, 2026

  • 6 min